Skip to main content
    U

    Unicycive Therapeutics Inc (UNCY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.70
    +0.00 (+0.00%)

    Market Cap: $97.25M

    Last updated: Nov 17, 2026 at 4:43 PM ET

    Unicycive Therapeutics Inc (UNCY) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Unicycive Therapeutics (UNCY) has a market cap of $97.25M and an enterprise value of $55.28M. Its share count is up 56.49% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 43.15% below the market cap, as cash exceeds debt.

    Market Cap$97.25M
    Enterprise Value$55.28M
    Latest price (Nov 17, 2026)$3.70

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 5.03% in the quarter ended Sep 30, 2026 and grew 78.28% a year over 2 years.

    Shares Outstanding28.27M
    Shares Change (YoY)+56.49%
    Shares Change (QoQ)+5.03%
    Share Count Growth (2Y CAGR)+78.28%

    Valuation Ratios

    Forward P/S71.0x
    P/B Ratio2.0x

    Price Statistics

    The stock is down 34.74% over 52 weeks and trades 10.63% below its 50-day average.

    Beta (1Y)1.11
    52-Week Change-34.74%
    1-Month Change+5.41%
    3-Month Change-33.69%
    6-Month Change-52.13%
    5-Year Change-87.06%
    Total Return (1Y)-34.74%
    Total Return (3Y CAGR)-9.71%
    Total Return (5Y CAGR)-32.05%
    Return vs SPY (1Y)-49.06%
    Max Drawdown (1Y)-60.75%
    Max Drawdown (3Y)-86.82%
    Sharpe Ratio (1Y)-0.56
    Correlation with SPY (1Y)0.18
    50-Day Average$4.14
    200-Day Average$5.92
    52-Week Range$3.33 to $8.74
    RSI (14 Days)46.6
    Average Volume (20 Days)1.06M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.00x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.00x
    Quick Ratio4.00x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -68.81% and return on assets is -51.78% over the last 12 months.

    Return on Equity (ROE)-68.81%
    Return on Assets (ROA)-51.78%
    ROIC (5Y Average)-71.93%

    Scores

    UNCY has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$151.00K
    Operating Income-$34.64M
    Pretax Income-$36.21M
    Net Income-$36.21M
    Reported EPS (TTM)-$1.67

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 75.25% of the $69.93M in total assets.

    Cash and Equivalents$41.97M
    Total Debt$0
    Net Cash$41.97M
    Net Cash Per Share$1.48
    Working Capital$51.85M
    Shareholder Equity$52.62M
    Book Value Per Share$1.86
    Total Assets$69.93M
    Total Liabilities$17.31M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $230.00K of capital spending, operating cash flow left -$29.36M of free cash flow.

    Operating Cash Flow-$29.13M
    Capital Expenditures$230.00K
    Free Cash Flow-$29.36M
    FCF Per Share-$1.07
    Depreciation and Amortization$587.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    UNCY does not pay a dividend. Its free cash flow yield is -28.06%.

    FCF Yield-28.06%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-10 reverse split on Jun 20, 2025.

    Last Split DateJun 20, 2025
    Split TypeReverse split
    Split Ratio1:10

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About UNCY

    What is UNCY's market cap?

    Unicycive Therapeutics has a market cap of $97.25M. Its enterprise value, which adds debt and subtracts cash, is $55.28M.

    How many shares of UNCY are outstanding?

    Unicycive Therapeutics has 28.27M shares outstanding. The count is up 56.49% from a year earlier.

    Does UNCY pay a dividend?

    No. Unicycive Therapeutics does not pay a dividend.

    How much debt does UNCY have?

    Unicycive Therapeutics has $0 of total debt and $41.97M of cash and equivalents, a net cash position of $41.97M.